2015, Number 3
<< Back Next >>
Ann Hepatol 2015; 14 (3)
Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism
Federico A, Aitella E, Sgambato D, Savoia A, De Bartolomeis F, Dallio M, Ruocco E, Pezone L, Abbondanza C, Loguercio C, Astarita C
Language: Spanish
References: 35
Page: 420-424
PDF size: 129.12 Kb.
ABSTRACT
The HCV protease inhibitor telaprevir associated with peginterferon–alpha and ribavirin, was widely used in
the recent past as standard treatment in HCV genotype-1 infected patients. Telaprevir improves the sustained
virology response rates, but at the same time increases the frequency of adverse cutaneous reactions.
However, mechanisms through which telaprevir induces cutaneous lesions are not yet defined. A
50-year-old woman, affected by HCV genotype 1b, was admitted to our Department for a telaprevir-related
severe cutaneous eruptions, eight weeks after starting a triple therapy (telaprevir associated with
Peginterferon-alpha and ribavirin). Mechanisms of cutaneous reactions were investigated by skin tests
with non-irritating concentrations of telaprevir and by activating
in vitro T lymphocyte with different
concentrations. Immediate and delayed responses to skin testing were negative, but the drug-induced
lymphocytes activation was significantly higher as compared to patient’s baseline values and to parallel
results obtained in three healthy subjects (p ‹ 0.05). In conclusion, adverse cutaneous reactions of our
patient were caused by a telaprevir-induced T-cell dependent immune mechanism.
REFERENCES
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, Hézode C, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012; 56: 455-63.
Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, et al. Telaprevir-Related Dermatitis. JAMA Dermatol 2013; 149: 152-8.
Picard O, Cacoub P. Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. Clin Res Hepatol Gastroenterol 2012; 36: 437-40.
Kwong Ann D, Kauffman Robert S, Hurter P. & Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nature Biotechnology 2011; 29: 993-1003.
Chawla A, Repa JJ, Evans RM & Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-70.
Palm Noah W, Rosenstein Rachel K. & Medzhitov R. Allergic host defences. Nature 2012; 484: 465-72.
Trépo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, Moreno C, et al. Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol 2011; 55: 38-44.
Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, Chosidow O, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009; 145: 67-72.
Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59: 809-20. Federico A, et al. , 2015; 14 (3): 420-424 424
Choi YW, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J. Interaction of Staphylococcus aureus toxin “superantigens” with human T cells. Proc Natl Acad Sci USA 1989; 86: 8941-5.
Mollick JA, Chintagumpala M, Cook RG, Rich RR. Staphylococcal exotoxin activation of T cells. Role of exotoxin-MHC class II binding affinity and class II isotype. J Immunol 1991; 146: 463-8.
Torres MJ, Mayorga C, Fernández TD, Cornejo-García JA, Antúnez C, Valenzuela M, Del Prado MF, et al. T cell assessment in allergic drug reactions during the acute phase according to the time of occurrence. Int J Immunopathol Pharmacol 2006; 19: 119-30.
Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, Bircher A, et al. Skin test concentrations for systemically administered drugs — an ENDA/ EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68: 702-12.
Torii H, Sueki H, Kumada H, Sakurai Y, Aoki K, Yamada I, Ohtsuki M. Dermatological side effects of Telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan. J Dermatol 2013; 40: 587-95.
European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007; 156: 1083-4.
Kaplan AP. Drug-induced skin disease. J Allergy Clin Immunol 1984; 74: 573-9.
Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30: 847-55.
Pichler WJ. Consequences of drug binding to immune receptors: Immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide- human leukocyte antigen or peptide. Dermatologica Sinica 2013; 31: 181-90.
Dupin N, Mallet V, Carlotti A, Vallet-Pichard A, Pol S. Severe Skin Rash in Case of Readministration of Telaprevir in a Patient Who Previously Experienced a Non Severe Rash. Hepatology 2012; 55: 2042-3.
Montaudié H, Passeron T, Cardot-Leccia N, Sebbag N, Lacour JP. Drug rash with eosinophilia and systemic symptoms due to Telaprevir. Dermatology 2010; 221: 303.
AusPAR Incivo Janssen-Cilag Pty Ltd PM-2010-03576-3-2; Page 20-21. Final 26 October 2012.
Lavergne SN, Park BK, Naisbitt DJ. The Roles of Drug Metabolism in the Pathogenesis of T-cell-Mediated Drug Hypersensitivity. Curr Opin Allergy Clin Immunol 2008; 8: 299-307.
Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, Unadkat JD. The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). Clin Pharmacol Ther 2004; 76: 313-22.
Oesch F, Fabian E, Oesch-Bartlomowicz B, Werner C, Landsiedel R. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev 2007; 39: 659-98.
Sieben S, Baron JM, Blomeke B, Merk HF. Multiple cytochrome P450-isoenzymes mRNA are expressed in dendritic cells. Int Arch Allergy Immunol 1999; 118: 358-61.
Siest G, Jeannesson E, Marteau JB, Samara A, Marie B, Pfister M, Visvikis-Siest S. Transcription factor and drugmetabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab Dispos 2008; 36: 182-9.
Lavergne SN, Kurian JR, Bajad SU, Maki JE, Yoder AR, Guzinski MV, Graziano FM, et al. Roles of endogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso. Toxicology 2006; 222: 25-36.
Pichler WJ. Delayed drug hypersensitivity reactions. Ann Internal Med 2003; 139: 683-93.
Seguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003; 3: 235-42.
Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kudo M, Chuganji Y, Tsukuda Y, et al; NORTE Study Group. Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. Hepatol Res 2014 [Epub ahead of print].
Weston JK, Uetrecht J. Activation of Inflammasomes by agents causing idiosyncratic skin reaction: a possible biomarker. Chem Res Toxicol 2014; 27: 949-51.
Romano A, Viola M, Gaeta F, Rumi G, Maggioletti M. Patch testing in non-immediate drug eruptions. Allergy Asthma Clin Immunol 2008; 4: 66-74.
Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K, Pichler WJ, et al; ENDA; EAACI. Diagnosis of no immediate reactions to beta-lactam antibiotics. Allergy 2004; 59: 1153-60.
Full text